Reading BRKR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BRKR free→Reading BRKR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BRKR free→
NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality cannot be assessed as the company was unprofitable over the past year. Management's recent track record has been fairly steady, while risk is elevated and the sector backdrop is a headwind. Peer multiples imply a price about 36% below where it trades (it looks expensive on this basis); the read is fair, but weakening. If BRKR cuts guidance on the next call, that could have a meaningful negative impact. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $55.80. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $56 BRKR trades at 40× p/e — 1.7× the 23× p/e peer median, and above its own 29× history. The market is re-rating it beyond its own range; our $41 fair value is medium-confidence here. Analysts: $45–$53. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The market is pricing in roughly 36% near-term growth, well above our forecast of about 2%. This describes what's priced in, not a forecast of the move.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted -12.42x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
6 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $0.38. 0 raised, 11 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 64% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$195.
How much price usually moves either way.
On a bad day, this stock has moved -$485.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $3,985.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation label changed from 'expensive' to 'full'.
The valuation changed, moving from "expensive" to "full." Risk fell. The sector backdrop remains a headwind. Recent financial performance is strong, but earnings quality is described as loss-making.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: If the company grows again, it will help meet FY26 revenue goals. This shows recovery.
Confirms:Q2 organic revenue growth reported above 0% year over year.
Disproves:Q2 organic revenue growth remains negative year over year.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Signals growth aligns with revenue guidance.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 6, 2026, Bruker Corporation issued a press release announcing financial results as of and for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any f…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$45.00 – $53.00 (median $45.00) · 3 analysts · as of 2026-05-08
Looks more expensive than peers.
Richer than its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
BRKR Bruker | Typical Show detailsSector percentile: 51 of 100 | full | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 92 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 70 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Bruker aims to achieve its FY2026 revenue guidance of $3.57 to $3.60 billion.
Bruker is committed to achieving its FY2026 non-GAAP EPS guidance of $2.10 to $2.15.
Bruker declared a quarterly cash dividend of $0.05 per share.
Why it matters: Strong bookings from new products can indicate market demand and growth potential.
Confirms:Bookings from new products rise a lot from one quarter to the next.
Disproves:Bookings from new products show little to no growth quarter over quarter.
Indicates growth concerns impacting revenue expectations.
End market growth supports revenue guidance.
New product launch enhances competitive position.
Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's common stock, $0.01 par value per share, of $0.05 per share. The dividend was declared on May 14, 2026, and is payable July 7, 2026, to shareholders of record at the close of business on June 22, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly a…
Other Events. The Board of Directors of Bruker Corporation declared a quarterly cash dividend on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, $0.01 par value per share, of $3.9844 per share. The dividend was declared on April 28, 2026, and is payable June 1, 2026, to shareholders of record at the close of business on May 15, 2026. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Election of New Director On March 27, 2026, the Board of Directors (the “Board”) of Bruker Corporation (the “Company”) approved an increase in the number of directors to expand the size of the Board by one director to a total of twelve directors, with such additional director assigned to Class III, and appointed Thierry L. Bernard to fill the n…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 6, 2026, Bruker Corporation (the “Company”) and Falko Busse, Ph.D., an executive officer of the Company and President of the Bruker BioSpin Group (“Bruker BioSpin”), a wholly owned subsidiary of the Company, agreed that his duties as executive officer with the Company and as President of Bruker BioSpin would transition on or around May 1,…